Steroid Sparing Immunosuppression in Management of Cardiac Sarcoidosis: A Systematic Review

•There is a lack of high-quality evidence for drug-modifying anti-sarcoidosis drugs (DMASD) in management of cardiac sarcoidosis.•Methotrexate is the most commonly used DMASD, followed by mycophenolate mofetil and azathioprine.•Tumour necrosis factor-α inhibitors use has primarily been described for refractory cardiac sarcoidosis.•Randomized controlled trials are needed to assess the efficacy of DMASDs in long-term management of cardiac sarcoidosis.